ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Gossamer Bio Inc

Gossamer Bio Inc (GOSS)

0.52
0.0033
(0.64%)
Closed June 15 4:00PM
0.5134
-0.0066
(-1.27%)
After Hours: 7:06PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
0.5134
Bid
0.515
Ask
0.54
Volume
731,761
0.513 Day's Range 0.53
0.4525 52 Week Range 1.88
Market Cap
Previous Close
0.5167
Open
0.5238
Last Trade
5
@
0.5134
Last Trade Time
Financial Volume
$ 380,734
VWAP
0.520299
Average Volume (3m)
1,580,620
Shares Outstanding
225,582,250
Dividend Yield
-
PE Ratio
-0.65
Earnings Per Share (EPS)
-0.8
Revenue
-
Net Profit
-179.82M

About Gossamer Bio Inc

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth,... Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Gossamer Bio Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker GOSS. The last closing price for Gossamer Bio was $0.52. Over the last year, Gossamer Bio shares have traded in a share price range of $ 0.4525 to $ 1.88.

Gossamer Bio currently has 225,582,250 shares outstanding. The market capitalization of Gossamer Bio is $117.30 million. Gossamer Bio has a price to earnings ratio (PE ratio) of -0.65.

GOSS Latest News

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension...

Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension...

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension...

Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update

- Transformative Development and Co-Commercialization Collaboration with Chiesi - - Ongoing PROSERA Phase 3 Study in PAH Expected to Readout in Q4 2025 - - Registrational Phase 3 in PH-ILD...

Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications

- Gossamer to receive $160 million development reimbursement payment and eligible to receive up to $146 million in regulatory and $180 million in sales milestones - - Gossamer leading US...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0866-14.43333333330.60.62670.499314339440.51985594CS
4-0.2266-30.62162162160.740.7450.499310935540.58378897CS
12-0.8366-61.97037037041.351.40.499315806200.80826556CS
26-0.5766-52.89908256881.091.60.499313824490.95257771CS
52-0.7666-59.8906251.281.880.452518531370.98411758CS
156-8.3366-94.19887005658.8515.1950.452518446163.65178763CS
260-18.8766-97.352243424419.3927.14970.452513346275.31729705CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
KAVLKaival Brands Innovations Group Inc
$ 5.96
(338.24%)
70.99M
LRHCLa Rosa Holdings Corporation
$ 1.165
(90.61%)
40.6M
SVMHSRIVARU Holding Ltd
$ 0.227586
(49.24%)
276.03M
BRFHBarfresh Food Group Inc
$ 3.03
(38.36%)
247.31k
NNENano Nuclear Energy Inc
$ 9.37
(32.53%)
1.77M
NXLNexalin Technologies Inc
$ 0.89
(-35.52%)
3.93M
INABIN8bio Inc
$ 1.095
(-34.82%)
4.92M
QXOQXO Inc
$ 134.10
(-34.71%)
142.29k
GANXGain Therapeutics Inc
$ 1.24
(-34.39%)
3.09M
KYTXKyverna Therapeutics Inc
$ 9.52
(-34.07%)
4.31M
NVDANVIDIA Corporation
$ 131.88
(1.75%)
309.34M
SVMHSRIVARU Holding Ltd
$ 0.227586
(49.24%)
276.03M
KITTNauticus Robotics Inc
$ 0.1921
(19.69%)
165.83M
CRKNCrown Electrokinetics Corporation
$ 0.0582
(-21.35%)
136.77M
SQQQProShares UltraPro Short QQQ
$ 8.43
(-1.29%)
112.46M

GOSS Discussion

View Posts
Termite7 Termite7 3 weeks ago
Assuming phase 3 approval, what price? Thanks!!!
πŸ‘οΈ0
FlippinNDippin FlippinNDippin 2 months ago
Took a starter here. GLTA
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
GOSS under $2
πŸ‘οΈ0
glenn1919 glenn1919 3 months ago
GOSS..........................................https://stockcharts.com/h-sc/ui?s=GOSS&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
glenn1919 glenn1919 4 months ago
GOSS..................................https://stockcharts.com/h-sc/ui?s=GOSS&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
glenn1919 glenn1919 4 months ago
GOSS......................................https://stockcharts.com/h-sc/ui?s=GOSS&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
Monksdream Monksdream 4 months ago
GOSS under $2
πŸ‘οΈ0
Monksdream Monksdream 9 months ago
GOSS new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 9 months ago
GOSS new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 9 months ago
GOSS new 52 week low
πŸ‘οΈ0
Dutch4 Dutch4 1 year ago
Agreed!
πŸ‘οΈ0
hippityhop hippityhop 1 year ago
Institutionals shorting this unmercilessly. Three trades totalling 2.4M total shares bought at 4 pm. @ .20 cent profit a share come to $468k.
πŸ‘οΈ0
hippityhop hippityhop 1 year ago
This is a 100/200 percenter in next 3 months, buy this now or weep later!!
πŸ‘οΈ0
crudeoil24 crudeoil24 2 years ago
Raymond James Initiates Coverage On Gossamer Bio with Outperform Rating, Announces Price Target of $19
7:13 am ET April 18, 2022 (Benzinga) Print
Raymond James analyst Timur Ivannikov initiates coverage on Gossamer Bio (NASDAQ:GOSS) with a Outperform rating and announces Price Target of $19.

Latest Ratings for GOSS DateFirmActionFromTo

Nov 2021SVB LeerinkMaintainsOutperform Aug 2021SVB LeerinkMaintainsOutperform Mar 2021HC Wainwright & Co.ReiteratesBuy
πŸ‘οΈ0
crudeoil24 crudeoil24 2 years ago
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. The Company's product candidates include Seralutinib (GB002), GB004, GB5121 and GB7208. GB002 is an inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R) and c-KIT inhibitor in development for the treatment of pulmonary arterial hypertension (PAH). GB004 is a gut-targeted, oral small molecule being developed for the treatment of inflammatory bowel disease (IBD). GB5121 is an oral, irreversible, covalent, small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK), in clinical development for the treatment of primary central nervous system lymphoma (PCNSL). GB7208 is an oral, small molecule, BTK inhibitor in preclinical development for the treatment of multiple sclerosis (MS).
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock